Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

October 17, 2013

Trial Date Set For BSX Vaginal Mesh Cases

The first of 6,400 lawsuits against Boston Scientific (BSX) regarding the Natick-based company’s transvaginal mesh devices will go to trial March 10, a lower-court judge ruled last week.

More than 30,000 suits have been filed against six transvaginal mesh manufacturers by woman alleging they suffered complications from the product aimed at treating involuntary urine leakage and pelvic organ protrusion.

The first four cases against BSX will serve as bellweather trials, a West Virginia district court judge ruled, meaning the plantiffs must be between 40 and 60 years old and have required up to three corrective surgeries. The first two trials involve allegations with Boston Scientific’s Pinnacle transvaginal mesh, while the following two involve the company’s Obtryx mesh.  

Reported complications from the product include mesh erosion, infection, severe pain and internal injuries.

“Transvaginal mesh remains an important treatment option and we continue to work with the U.S. Food and Drug Administration to ensure appropriate information regarding mesh products is provided to patients and doctors,” Boston Scientific said in a statement.

A West Virginia jury found C.R. Bard Inc. liable in August for $2 million in damages in a transvaginal mesh case. In March, a New Jersey jury found Ethicon liable for $11 million in damages from its own mesh product.

The West Virigina judge noted last month that several companies, including Boston Scientific, were considering settlement talks.  

Read more

BSX Sees Improvement In Q2

Boston Scientific Issues $1B In Debt Notes

Medical Journal Boosts Boston Scientific Device

Boston Scientific Sued Over Pacemaker Deal, Settles Patent Suit

BSX Cuts More Jobs as Q3 Loss Shrinks

Sign up for Enews

WBJ Web Partners

Related Content

0 Comments

Order a PDF